Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Van der Jeught

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Surgical Oncology Clinics of North America|March 28, 2026
Disrupting the Immunosuppressive Myeloid Compartment in Solid TumorsManan Patel, Kevin Van der Jeught, Jashodeep Datta
Oncoimmunology|July 9, 2015
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapyKevin Van der Jeught, Sandra Van Lint, Kris Thielemans, et al.
World Journal of Gastroenterology|September 20, 2018
Drug resistance and new therapies in colorectal cancerKevin Van der Jeught, Han-Chen Xu, Yu-Jing Li, et al.
New Biotechnology|March 26, 2018
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20Ahmet Krasniqi, Magdalena Bialkowska, Catarina Xavier, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
Adjuvant-Enhanced mRNA VaccinesLukasz Bialkowski, Kevin Van der Jeught, Dries Renmans, et al.
International Journal of Cancer|February 22, 2018
Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapyLukasz Bialkowski, Kevin Van der Jeught, Sanne Bevers, et al.
Oncotarget|October 23, 2014
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunityKevin Van der Jeught, Patrick Tjok Joe, Lukasz Bialkowski, et al.
Molecular Cancer Therapeutics|October 22, 2017
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin LymphomaAhmet Krasniqi, Matthias D'Huyvetter, Catarina Xavier, et al.
Molecular Therapy. Nucleic Acids|June 22, 2016
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I InterferonKatrijn Broos, Kevin Van der Jeught, Janik Puttemans, et al.
Oncotarget|February 16, 2015
Targeting the tumor microenvironment to enhance antitumor immune responsesKevin Van der Jeught, Lukasz Bialkowski, Lidia Daszkiewicz, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Surgical Oncology Clinics of North America|March 28, 2026
Disrupting the Immunosuppressive Myeloid Compartment in Solid TumorsManan Patel, Kevin Van der Jeught, Jashodeep Datta
Oncoimmunology|July 9, 2015
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapyKevin Van der Jeught, Sandra Van Lint, Kris Thielemans, et al.
World Journal of Gastroenterology|September 20, 2018
Drug resistance and new therapies in colorectal cancerKevin Van der Jeught, Han-Chen Xu, Yu-Jing Li, et al.
New Biotechnology|March 26, 2018
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20Ahmet Krasniqi, Magdalena Bialkowska, Catarina Xavier, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
Adjuvant-Enhanced mRNA VaccinesLukasz Bialkowski, Kevin Van der Jeught, Dries Renmans, et al.
International Journal of Cancer|February 22, 2018
Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapyLukasz Bialkowski, Kevin Van der Jeught, Sanne Bevers, et al.
Oncotarget|October 23, 2014
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunityKevin Van der Jeught, Patrick Tjok Joe, Lukasz Bialkowski, et al.
Molecular Cancer Therapeutics|October 22, 2017
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin LymphomaAhmet Krasniqi, Matthias D'Huyvetter, Catarina Xavier, et al.
Molecular Therapy. Nucleic Acids|June 22, 2016
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I InterferonKatrijn Broos, Kevin Van der Jeught, Janik Puttemans, et al.
Oncotarget|February 16, 2015
Targeting the tumor microenvironment to enhance antitumor immune responsesKevin Van der Jeught, Lukasz Bialkowski, Lidia Daszkiewicz, et al.
Pageof 4